Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focusesOn |
oncology
precision medicine targeted cancer therapies |
| gptkbp:foundedYear |
2013
|
| gptkbp:founder |
gptkb:Athena_Countouriotis
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Turning Point Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:repotrectinib
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:TPTX
|
| gptkbp:website |
https://www.tptherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:bfsLayer |
6
|